Skip to content

Apogee Therapeutics, Inc. APGE Investing Cash Flow

Investing Cash Flow at other companies

Eli Lilly logo
Eli LillyLLY
-$3.92B-16.8%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
-$428.9M-166%
AbbVie logo
AbbVieABBV
-$574M+21.9%
Summit Therapeutics logo
Summit TherapeuticsSMMT
-$238K-100%
Immunovant, Inc. logo
Immunovant, Inc.IMVT
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX

Other financials

Income statement

See full
Operating income-$82.8M-31.2%
Net income-$74.1M-33.9%
EPS (diluted)-$1.06-11.6%

Balance sheet

See full
Cash & equivalents$451.8M+323%
Total debt$8.0M-31.9%
Total assets$1.3B+81.1%

Cash flow

See full
Operating cash flow-$55.6M-14.6%
CapEx$62.0K
Free cash flow-$62.8M+7.3%

Valuation

See full
Market cap$6.81B+189%
Enterprise value$6.37B+181%

Returns & leverage

See full
Current ratio32.6×+16.8×

Where this comes from

Reported directly by Apogee Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: Apogee Therapeutics, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Apogee Therapeutics, Inc.'s investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Apogee Therapeutics, Inc.'s investing cash flow?
Apogee Therapeutics, Inc. (APGE) reported investing cash flow of -$35.35M in Q1 2026.
How has Apogee Therapeutics, Inc.'s investing cash flow changed year-over-year?
Apogee Therapeutics, Inc.'s investing cash flow decreased by 372.3% year-over-year, from $12.98M to -$35.35M.
What does investing cash flow mean?
Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.